ArticleEuropean heart journal. Case reports2026
A diagnostic challenge of advanced-stage cardiac Fabry disease without left ventricular hypertrophy: a case report.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fabry disease is a rare, X-linked lysosomal storage disorder, leading to α-galactosidase A deficiency. The primary cardiac involvement is left ventricular (LV) hypertrophy (LVH), which can progress to LV dysfunction, heart failure, and fatal arrhythmias. We present a diagnostically challenging case of advanced-stage cardiac Fabry disease with worsening LV dysfunction without LVH. Case summary: A 72-year-old woman with a family history of dilated cardiomyopathy was referred for regular follow-up. The initial electrocardiogram 14 years ago showed a shortened PQ interval minus the P-wave interval and inverted T waves; however, LVH was not observed. Three years prior, echocardiography revealed inferolateral wall thinning, and computed tomography and magnetic resonance imaging confirmed fatty infiltration and transmural late gadolinium enhancement in the thinned inferolateral wall. Two years later, she was admitted for heart failure, with LV ejection fraction decreasing to 29%. Owing to progressive LV dysfunction and family history, comprehensive genetic testing was performed, identifying a pathogenic Discussion: This case demonstrates that advanced-stage cardiac Fabry disease can progress to LV dysfunction, wall thinning, and fibrosis in the absence of prior LVH. Electrocardiogram abnormalities and multimodal imaging findings, such as wall thinning, fatty infiltration, and late gadolinium enhancement, are key indicators of cardiac Fabry disease. This case emphasizes the importance of comprehensive evaluation for early diagnosis, including electrocardiography, echocardiography, computed tomography, and magnetic resonance imaging, even without LVH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.